2 results
Ten new insights in climate science 2022
- Maria A. Martin, Emmanuel A. Boakye, Emily Boyd, Wendy Broadgate, Mercedes Bustamante, Josep G. Canadell, Edward R. Carr, Eric K. Chu, Helen Cleugh, Szilvia Csevár, Marwa Daoudy, Ariane de Bremond, Meghnath Dhimal, Kristie L. Ebi, Clea Edwards, Sabine Fuss, Martin P. Girardin, Bruce Glavovic, Sophie Hebden, Marina Hirota, Huang-Hsiung Hsu, Saleemul Huq, Karin Ingold, Ola M. Johannessen, Yasuko Kameyama, Nilushi Kumarasinghe, Gaby S. Langendijk, Tabea Lissner, Shuaib Lwasa, Catherine Machalaba, Aaron Maltais, Manu V. Mathai, Cheikh Mbow, Karen E. McNamara, Aditi Mukherji, Virginia Murray, Jaroslav Mysiak, Chukwumerije Okereke, Daniel Ospina, Friederike Otto, Anjal Prakash, Juan M. Pulhin, Emmanuel Raju, Aaron Redman, Kanta K. Rigaud, Johan Rockström, Joyashree Roy, E. Lisa F. Schipper, Peter Schlosser, Karsten A. Schulz, Kim Schumacher, Luana Schwarz, Murray Scown, Barbora Šedová, Tasneem A. Siddiqui, Chandni Singh, Giles B. Sioen, Detlef Stammer, Norman J. Steinert, Sunhee Suk, Rowan Sutton, Lisa Thalheimer, Maarten van Aalst, Kees van der Geest, Zhirong Jerry Zhao
-
- Journal:
- Global Sustainability / Volume 5 / 2022
- Published online by Cambridge University Press:
- 10 November 2022, e20
-
- Article
-
- You have access Access
- Open access
- HTML
- Export citation
-
Non-technical summary
We summarize what we assess as the past year's most important findings within climate change research: limits to adaptation, vulnerability hotspots, new threats coming from the climate–health nexus, climate (im)mobility and security, sustainable practices for land use and finance, losses and damages, inclusive societal climate decisions and ways to overcome structural barriers to accelerate mitigation and limit global warming to below 2°C.
Technical summaryWe synthesize 10 topics within climate research where there have been significant advances or emerging scientific consensus since January 2021. The selection of these insights was based on input from an international open call with broad disciplinary scope. Findings concern: (1) new aspects of soft and hard limits to adaptation; (2) the emergence of regional vulnerability hotspots from climate impacts and human vulnerability; (3) new threats on the climate–health horizon – some involving plants and animals; (4) climate (im)mobility and the need for anticipatory action; (5) security and climate; (6) sustainable land management as a prerequisite to land-based solutions; (7) sustainable finance practices in the private sector and the need for political guidance; (8) the urgent planetary imperative for addressing losses and damages; (9) inclusive societal choices for climate-resilient development and (10) how to overcome barriers to accelerate mitigation and limit global warming to below 2°C.
Social media summaryScience has evidence on barriers to mitigation and how to overcome them to avoid limits to adaptation across multiple fields.
The use of ziprasidone in clinical practice: Analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey
- Friederike Vogel, Reinhard Gansmüller, Thomas Leiblein, Otto Dietmaier, Hans Wassmuth, Gerhard Gründer, Christoph Hiemke
-
- Journal:
- European Psychiatry / Volume 24 / Issue 3 / April 2009
- Published online by Cambridge University Press:
- 16 April 2020, pp. 143-148
-
- Article
- Export citation
-
This study related clinical effects to daily doses and serum concentrations of ziprasidone by retrospective analysis of data from a therapeutic drug monitoring (TDM) survey established for patients treated with the new antipsychotic drug. In the total sample of 463 patients ziprasidone doses ranged between 20 and 320 mg/d and correlated significantly (r2 = 0.093, P < 0.01) with serum concentrations. The latter were highly variable within and between individual patients (between patients median 67 ng/ml, 25–75th percentile 40–103 ng/ml). Pharmacokinetic interactions with comedication played a minor role. According to the clinical global impressions (CGI) scale most of the 348 patients who were under antipsychotic monotherapy with ziprasidone were either much or very much improved (43.3 and 17.3%, respectively). The previously proposed therapeutic range of 50–130 ng/ml ziprasidone in serum or plasma, which can in effect be used interchangeable, was confirmed. In patients who were at least much improved and defined as “responders” mean serum concentrations of ziprasidone were 80 ng/ml and 78 ng/ml in patients who did not reach this improvement score. In patients with serum levels above or below 50 ng/ml, the number of responders was 66 or 63%, respectively. The difference between the two groups was not significant (P = 0.375), and improvement or side effects did not correlate significantly (P > 0.05) with doses or serum levels. It is concluded that TDM of ziprasidone may be useful for treatment optimization because of highly variable serum concentrations resulting under therapeutically recommended doses of the drug.